1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Amgen Inc.

Amgen Inc.

AMGN.TO
Amgen Inc.CA flagToronto Stock Exchange
29.80
CAD
-0.43
- -
16.11BMarket Cap
Amgen Inc.
AMGN.TO
(Toronto Stock Exchange)

Recent

price

29.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.86
0.95
1.23
1.37
1.45
1.57
1.69
1.72
1.98
2.13
2.39
2.51
2.69
2.9
3.43
3.76
3.89
Revenue per Share
0.27
0.22
0.31
0.37
0.37
0.5
0.57
0.15
0.7
0.71
0.68
0.57
0.67
0.69
0.42
0.79
0.89
Basic EPS, GAAP
0.3
0.28
0.37
0.41
0.58
0.66
0.7
0.79
0.88
0.78
0.93
0.81
0.9
0.76
1.07
0.83
1.04
Free Cash Flow per Basic Share
- -
0.03
0.08
0.1
0.13
0.17
0.22
0.25
0.29
0.32
0.35
0.39
0.43
0.47
0.5
0.52
0.54
Dividend per Share
25.69
23.92
25.2
29.28
33.9
37.25
40.48
34.95
19.85
16.36
16.27
12
6.86
11.64
10.94
16.07
21.62
Book Value per Share
11.14
5.9
3.21
-8.13
-2.24
2.19
6.57
2.59
-15.31
-41.33
-37.81
-41.86
-52.34
-84.12
-75.34
-59.94
-50.81
Tangible Book Value per Share
17,442
16,442
14,081
13,681
13,790
13,772
13,590
13,281
12,009
10,992
10,647
10,356
9,775
9,720
9,756
9,775
9,805
Basic Weighted Avg Shares
15,053
15,582
17,265
18,676
20,063
21,662
22,991
22,849
23,747
23,362
25,424
25,979
26,323
28,190
33,424
36,751
38,095
Sales/Revenue/Turnover
36.84
27.67
32.3
31.41
30.86
39.1
42.6
43.65
43.22
41.41
35.95
29.4
36.34
28.01
21.71
24.71
29.99
Operating Margin (%)
1,017
1,060
1,088
1,286
2,092
2,108
2,105
1,955
1,946
2,206
3,601
3,398
3,417
4,071
5,592
5,167
4,667
Depreciation Expense
4,627
3,683
4,345
5,081
5,158
6,939
7,722
1,979
8,394
7,842
7,264
5,893
6,552
6,717
4,090
7,711
8,743
Net Income, GAAP
12.98
11.25
13.26
3.49
7.65
13.02
15.73
79.38
12.06
14.18
10.68
12.06
10.81
14.49
11.26
14.09
15.01
Effective Tax Rate (%)
30.74
23.64
25.17
27.21
25.71
32.03
33.59
8.66
35.35
33.57
28.57
22.68
24.89
23.83
12.24
20.98
22.95
Profit Margin (%)
16,559
21,839
23,018
19,420
27,705
29,851
34,806
40,456
24,130
5,605
9,491
7,201
6,499
11,940
5,931
3,568
9,459
Working Capital
10,874
21,344
24,034
29,623
30,215
29,182
30,193
34,190
29,510
26,950
32,895
33,222
37,354
63,170
56,549
50,005
51,859
LT Debt
23,944
19,029
19,060
22,096
25,778
28,083
29,875
25,241
12,500
9,673
9,409
6,700
3,661
6,232
5,877
8,658
11,688
Total Equity
13.67
9.84
11.24
11.35
10.33
12.7
13.31
3.29
16.87
19.18
19.58
16.01
20.19
11.61
9.13
11.8
14.64
Return on Invested Capital (%)
14.6
10.86
12.22
12.16
11.1
13.61
14.17
3.6
17.98
20.81
20.47
16.86
18.9
16.18
10.07
15.6
16.6
Return on Capital (%)
19.85
17.14
22.81
24.69
21.55
25.77
26.65
7.18
44.48
70.73
76.13
73.16
126.47
135.79
67.55
106.1
91.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,599
5,437
5,445
LT Borrowings
50,005
51,886
51,859
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
539
540
541
Market Capitalization
9,746
10,107
10,245

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
29,057
31,475
34,961
Cash, Cash Equivalents & STI
9,129
12,038
13,989
Accounts Receivable, Net
9,570
9,138
10,227
Inventories
6,225
6,186
6,220
Total Current Liabilities
25,489
24,955
25,502
Payables & Accruals
19,453
19,518
20,057
ST Debt
4,599
5,437
5,445
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.73%
7.54%
47.32%
Free Cash Flow
0.49%
-1.5%
-22.07%
Net Income, GAAP
29.14%
8.85%
88.53%
Sales/Revenue/Turnover
5.58%
7.82%
9.95%
Total Cash Common Dividend
8.08%
6.42%
6.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,447
8,388
8,503
9,086
33,424
2025
8,149
9,179
9,557
9,866
36,751
2026
8,618
10,054
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
0.08
0.29
0.06
0.42
2025
0.18
0.15
- -
0.14
0.79
2026
0.19
0.24
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.12
0.12
0.12
0.5
2025
0.13
0.13
- -
0.13
0.52
2026
0.14
0.14
- -
- -
- -
Similar Companies
Grifols, S.A. (GRFS)
Bayer Aktiengesellschaft (BAYN.SG)
Sanofi (SNY.TO)
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
SMS Pharmaceuticals Limited (SMSPHARMA.BO)
Astellas Pharma Inc. (4503.T)
Business
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures and delivers innovative human therapeutics for the treatment of serious diseases, with operations organized in one reportable segment, human therapeutics. Founded in 1980 and headquartered in Thousand Oaks, California, the company serves patients and healthcare providers across the United States and internationally, with a portfolio focused on oncology, inflammation, rare disease and general medicine. Its marketed and commercialized products include Repatha; Prolia; Evenity; Enbrel; Otezla; Neulasta; Neupogen; Epogen; Aranesp; Parsabiv; Sensipar/Mimpara; Blincyto; Imdelltra; Tezspire; Uplizna; Tavneos; and biosimilars and other biologics such as Kanjinti, Pavblu and Wezlana, alongside a pipeline spanning additional investigational therapies and lifecycle expansions. In recent periods, Amgen has expanded its biomanufacturing footprint with announced investments in North Carolina, Ohio and Puerto Rico; completed the acquisition of Dark Blue Therapeutics to strengthen its oncology pipeline; secured additional regulatory approvals and label expansions for products including Repatha, Uplizna, Tezspire and Imdelltra; and advanced collaboration-driven development programs, including its long-running partnership with AstraZeneca on Tezspire and related pipeline assets.